It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.95 [0.41, 2.17]
2 studies · 247 participants
Very low

Deferasirox vs deferiprone (DFO)

SAEs ‐ SCD‐related SAEs

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 195 participants
Very low

Deferasirox vs deferiprone (DFO)

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
0.96 [0.06, 15.42]
2 studies · 240 participants
Very low

Intervention not reported

Ferritin: final or change (µg/L) · adults and children with CKD

1 finding from 1 review

Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
no estimate extracted
33 studies · 3389 participants
Low

Intervention not reported

TSAT: final or change (%) · adults and children with CKD

1 finding from 1 review

Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
no estimate extracted
27 studies · 3089 participants
Low

Intervention not reported

HCT (%) · adults and children with CKD

1 finding from 1 review

Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 152 participants
Very low

Intervention not reported

ESA dose: final or change · adults and children with CKD

1 finding from 1 review

Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 522 participants
Low

Intervention not reported

eGFR: final or change (mL/min) · adults and children with CKD

1 finding from 1 review

Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1052 participants
Low

Intervention not reported

Number achieving target Hb or increase ≥1 g/dL · adults and children with CKD

The intervention may leads to higher number achieving target Hb or increase ≥1 g/dL (low certainty).

1 finding from 1 review

Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
RR 1.71 [1.43, 2.04]
13 studies · 2206 participants
Low

Intervention not reported

Hb: final or change (g/dL) · adults and children with CKD

1 finding from 1 review

Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
no estimate extracted
31 studies · 3373 participants
Low